Clinical Trials Browser

Phase 3 × Gallbladder Neoplasms × 1 year × Clear all

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Phase 3 Active not recruiting

757 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT06282575 2026-02-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Phase 3 Recruiting

286 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07265674 2026-01-23

Beacon-BTC

Phase 3 Recruiting

480 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04003636 2025-04-23

KEYNOTE-966

Phase 3 Completed

1,069 enrolled 19 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04924062 2025-04-17

MK-3475-966

Phase 3 Completed

158 enrolled 19 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06712420 2025-04-16

NEOGB

Phase 3 Recruiting

114 enrolled

Gastrointestinal

Gallbladder Neoplasms

NCT02170090 2025-03-30

ACTICCA-1

Phase 3 Active not recruiting

789 enrolled

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

Clinical Trials

AB02

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Beacon-BTC

KEYNOTE-966

MK-3475-966

NEOGB

ACTICCA-1